UHNM Joins Innovative TriNetX Health Research Network
STOKE-ON-TRENT, England, Sept. 26, 2016 /PRNewswire/ -- Research and Development at University Hospitals of North Midlands NHS Trust (UHNM) is the first healthcare organisation in the UK to sign a membership agreement with an innovative software company, TriNetX, to join its health research network.
Logo - http://photos.prnewswire.com/prnh/20160303/340354LOGO
The Research and Development Department at UHNM will now be part of a network with a far superior ability to query research data more efficiently and, most importantly, connect with other organisations from around the world. This landmark milestone will expand access to new treatment options for all patients at UHNM, as well as increase sponsored research revenue streams for the Trust.
Biopharmaceutical companies and contract research organisations (CROs) will be able to collaborate with UHNM through TriNetX to easily determine whether it is feasible for a clinical study to be conducted at the Trust. The network will also enable an efficient transition from a sponsor first approaching the department with a potential new study, to opening cutting-edge research within the hospital.
TriNetX works by securely connecting researchers to clinical data from healthcare organisations all over the world. Members can then engage with each other through the network, in order to collaborate on bringing the very latest clinical research trials to their sites.
Dr Darren Clement, R&D Manager at UHNM, said: "UHNM is delighted to be working in partnership with TriNetX on this project, as it means we will be able to offer our patients greater choice and increased access to cutting-edge treatments and therapies. We want UHNM to be the go-to hospital for patients wanting to access these new treatments, and working with TriNetX will help us deliver this vision for the benefit of our patients."
Gadi Lachman, CEO of TriNetX, Inc., said: "UHNM is a significant addition in the rapid international expansion of the TriNetX network. Today, UHNM attracts numerous sponsored clinical studies every year. TriNetX will help UHNM improve the identification of studies that are pre-qualified and feasible for its patient population, as well as support expansion of commercial research programmes, assist investigator-initiated studies and facilitate collaboration with peer organisations from all over the world."
Professor Tony Fryer, R&D Director at UHNM, said: "We are delighted to be the first UK Trust to join the TriNetX network. This collaboration will help us maximise our patients' access to state-of-the-art treatment that participation in clinical research provides."
Note to Editors:
The Research and Development Department at University Hospitals of North Midlands NHS Trust is a dedicated team committed to providing opportunities for the people of Staffordshire to access the latest treatments and innovations.
It is a centre for clinical research trials from around the world, offering patients the chance to take part in a number of initiatives. In 2015/2016, it ran a total of 385 trials, which were opened or in follow up. In the same financial year it generated grant income of £2.69M. The team has also diversified into the field of innovation and supports not just its own staff across the Trust, but also small to medium-sized businesses developing innovative ideas, such as equipment and ways of working to benefit patients and healthcare.
About TriNetX, Inc.
TriNetX is a worldwide health research network of healthcare organisations, biopharmaceutical companies and contract research organisations used to enhance clinical trial design and accelerate patient recruitment. TriNetX enables researchers to find the right patients at the right sites for clinical trials. For more information, visit http://www.trinetx.com.
Media inquiries:
Alannah Copeland, Marketing and Communications Officer
Research and Development
Tel: 01782 671092 e-mail: Alannah.Copeland@uhnm.nhs.uk
Share this article